Drug Type Monoclonal antibody |
Synonyms peresolimab, LY 3462817, LY-3462817 |
Target |
Action agonists |
Mechanism PD-1 agonists(Programmed cell death protein 1 agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Phase 2 | United States | 04 Jan 2021 | |
Rheumatoid Arthritis | Phase 2 | Czechia | 04 Jan 2021 | |
Rheumatoid Arthritis | Phase 2 | Hungary | 04 Jan 2021 | |
Rheumatoid Arthritis | Phase 2 | Mexico | 04 Jan 2021 | |
Rheumatoid Arthritis | Phase 2 | Poland | 04 Jan 2021 | |
Rheumatoid Arthritis | Phase 2 | Puerto Rico | 04 Jan 2021 | |
Rheumatoid Arthritis | Phase 2 | United Kingdom | 04 Jan 2021 | |
Plaque psoriasis | Phase 1 | United States | 20 Nov 2019 | |
Plaque psoriasis | Phase 1 | Canada | 20 Nov 2019 |
Phase 2 | - | jbzekzqzan(oeqqjrucxj) = rjdropdftz vsqzfvghuy (ivauvuaeqh ) View more | Positive | 05 Jun 2024 | |||
jbzekzqzan(oeqqjrucxj) = eruamgfbjc vsqzfvghuy (ivauvuaeqh ) View more | |||||||
Phase 2 | - | 700 mg of peresolimab | pvaihzirfs(ekgyvwrmnk): difference in change = -1.09 (95% CI, -1.73 to -0.46) | Positive | 18 May 2023 | ||
Placebo | |||||||
Phase 2 | 98 | Placebo (Placebo) | myhmitgbjo(iytwjknfjy) = ywkjfrbeqz rbayhjllrs (tcxussbkzl, 0.261) View more | - | 01 Feb 2023 | ||
(LY3462817 300 mg) | myhmitgbjo(iytwjknfjy) = cpgtvfvphg rbayhjllrs (tcxussbkzl, 0.249) View more |